Regeneron stock costs EUR 668.30 with USD 77.1 billion market cap

Published on 10/09/2026 at 19:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock gained 1.31 percent versus EUR 659.65 on October 9, 2026. Results are due October 30, 2026 before the U.S. open.

Key points in brief

Regeneron stock was EUR 668.30 at Lang & Schwarz after-hours on October 9, 2026, up 1.31 percent versus the prior close.
Regeneron had a USD 77.1 billion market capitalization and a P/E ratio of 18.5 as of October 9, 2026.
The Nasdaq quote was USD 747.94, 12.96 percent below the 52-week high of USD 859.34.
Regeneron is scheduled to report third-quarter 2026 results on October 30, 2026.

Aquarellmalerei eines modernen Forschungscampus mit Glastürmen am Flussufer — Regeneron Pharma US75886F1075 präsentiert eine stimmungsvolle Aquarell-Ansicht eines modernen Forschungscampus entlang eines ruhigen Flussufers, Illustration mit AI erstellt.

Regeneron stock was trading at EUR 668.30 at Lang & Schwarz on October 9, 2026 at 7:52 p.m. CEST, up 1.31 percent versus the prior close of EUR 659.65. Its market capitalization was USD 77.1 billion on the same date.

Price remains below yearly high

On Nasdaq, Regeneron was last at USD 747.94 at 1:57 p.m. ET on October 9, 2026. The USD 541.00 to USD 859.34 52-week range placed the stock 12.96 percent below its high.

Trading volume stood at 210,670 shares against an average of 736,976 shares on October 9, 2026. The current Nasdaq price was therefore 12.96 percent below the yearly peak while remaining USD 206.94 above the yearly low.

Valuation and analyst context

Regeneron traded at a P/E ratio of 18.5 and carried a USD 77.1 billion market capitalization as of October 9, 2026. The figures place the company below the valuation multiples of the two biotechnology peers listed below.

According to MarketBeat on October 7, 2026, Morgan Stanley raised its target from USD 758.00 to USD 779.00 while retaining an equal-weight rating. That analyst action is included as dated context, while the current euro quote remains the market report's central reference.

Comparison with peers

Regeneron: plus 1.31 percent, P/E 18.5, market capitalization USD 77.1 billion
Amgen (NYSE, USD): plus 2.38 percent, P/E 25.9, market capitalization USD 225.1 billion
Vertex Pharmaceuticals (NASDAQ, USD): plus 1.39 percent, P/E 29.7, market capitalization USD 129.5 billion

Next results date is October 30

Regeneron announced on September 24, 2026 that it will report third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. financial markets open. The company also scheduled its conference call for 8:30 a.m. ET that day.